CB-010: A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

Allogeneic CAR-T cell therapy is a type of cancer therapy in which a healthy donor’s T cells (a type of immune system cell that circulates in blood) are modified during manufacturing using CRISPR genome editing so that those T cells will detect and kill cancer cells and potentially stay in your blood long enough to treat the cancer. CRISPR technology is a tool to edit healthy donor T cell genomes and it uses enzymes that act like molecular scissors to cut and edit strands of DNA to produce a cancer therapy.